Of the PPACA Battle Lines, (Anti)Social Security & Hartford’s Dismemberment: What We’re Reading

Commentary March 29, 2012 at 02:00 AM
Share & Print

Every day the editors and reporters of LifeHealthPro share stories from around the web that they're reading. You can keep up with what we're reading on our Editor Picks page or by subscribing to our daily newsletter, where our daily picks are also featured.

Below is a list of our favorite stories from the past week. We hope you enjoy them. If you have any stories you'd like to share, please list them in the comments section below, and we'll share your picks with other readers through LifeHealthPro's Twitter page.

 

Agency plans to replace mailing annual paper statements with online version.

Economy slowly breaking free from the grip of recession.

FDA, drugmakers blame the other for increasing shortages of chemotherapy drugs, antibiotics, anesthetics and vaccines.

Separate study found 26,000 previously uninsured Americans cut health care costs by 50% after getting health care.

HHS spent $11.2 million promoting the law, U.S. Chamber of Commerce spent $6.3 million opposing it.

Annuities may make economic sense, but the market for them is somewhat bleak.

The Court's ruling on PPACA will have implications for the regulatory ability of the federal government to set long-term national policy goals.

People wait in line over 60 hours for a chance at one of 60 spots inside the Supreme Court building for the general public.

Hartford will stop selling new annuities, but must protect and service existing customers.

Could insiders writing op-ed pieces start structural and ethical reform of the finance industry?

Readers' Favorite LifeHealthPro Stories From the Past Week

 

#9           Bad Sales Habits You Need to Drop

#8           The Exchange Regulations Are Here

#6           Larger Than Life

#2           Hartford Exiting the Life Business

#1           8 Estate Planning Mistakes to Avoid

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Related Stories

Resource Center